Newspaper logo  
 
 
Local News & Opinion

Ref. : Civic Events

Ref. : Arts & Education Events

Ref. : Public Service Notices

Travel
Books, Films, Arts & Education

10.22 Vote all you want. The secret government won’t change.

Letters
Open Letters:

Ref. : Letters to the editor

Health Care & Environment

10.25 New front in war on Alzheimer's and other protein-linked brain diseases

10.25 Surgeons transplant heart that had stopped beating

10.25 Blocked on the Keystone XL, the Oil-Sands Industry Looks East

10.24 EU reaches deal on CO2 emissions cut

10.24 University of Pittsburgh study correlates autism with air pollution

10.24 University of Pittsburgh study correlates autism with air pollution

10.23 Five graphs that explain the EU 2030 energy and climate deal

10.22 Doctors Without Borders Hits Ebola Breaking Point

10.22 Ebola virus: how it spreads and what it does to you – video

10.22 WHO aims for Ebola serum in weeks and vaccine tests in Africa by January

10.22 What If America Had Canada's Healthcare System? [7:25 video, charts]

News Media

Daily FAIR Blog
The Daily Howler

Justice Matters

10.23 US jury convicts Blackwater guards in 2007 killing of Iraqi civilians

US Politics, Policy & Culture

10.25 Infographic: The Transfer Of Military Surplus To Domestic Police

10.25 Full Show: The Fight — and the Right — to Vote [25:23 video]

10.24 How Racial Equity Can Make Cities Richer [graphs]

10.24 Prenatal Air Pollution Linked to Impaired Lung Function

10.24 How Independents Could Seize Control of the Senate

10.23 The Era of Political Disruption

10.23 Rand Paul: The Most Interesting Conspiracy Theorist in Washington

10.23 Amid Shootings, Chicago Police Department Upholds Culture of Impunity

10.23 Chris Christie Pay-To-Play Probe Of Charlie Baker Takes Center Stage In Massachusetts Gubernatorial Debate

10.22 Yes, it's true: Police only shot four people (and nobody died) in all of England the past two years

10.22 The Best Investigative Reporting on Campaign Finance Since 2012

10.21 Warren Makes the Case

10.21 Texas Just Won the Right to Disenfranchise 600,000 People. It's Not the First Time. [A disgraceful history]

10.21 Yes, Mass Shootings Are Occurring More Often [graphs]

10.21 The Bottom 90 Percent: No Better Off Today Than in 1986

10.21 Can Homeless People Move Into Baltimore's Abandoned Houses?

10.21 Chart: Values of Homes Owned by African Americans Take Outsized Hit Compared to Those Owned by Whites

10.21 You might be a politician if ... you tried to defund Ebola research, only to campaign on Ebola fear

High Crimes?

10.22 White House Chief Of Staff Negotiating Redaction Of CIA Torture Report

10.22 Fred Branfman, exposer of America’s secret war in Laos, died on September 24th, aged 72

10.22 US ordered to explain withholding of Iraq and Afghanistan torture photos

Economics, Crony Capitalism

10.24 Compensation shrinks for all income groups – except the very highest

10.24 The Mortgage Industry Is Strangling the Housing Market and Blaming the Government

10.24 Elizabeth Warren Demands An Investigation Of Mortgage Companies

10.24 MyRA Accounts Fall Short for Savers

10.20 The Feds Just Approved a New GMO Corn. Here's Why I'm Not Rejoicing

10.20 EPA: Those Bee-Killing Pesticides? They're Actually Pretty Useless

International

10.25 Tunisia is showing the Arab world how to nurture democracy

10.24 Saudi Arabia's Women Problem

10.24 Boko Haram Abducts More Women, Despite Claims of Nigeria Cease-Fire

10.23 Thousands in Iran Protest Acid Attacks on Women

10.23 Death in the Sahara: An Ill-Fated Attempt to Reach Fortress Europe

10.23 Battle for Kobani: As the World Watches, Turkey Looks Away

10.23 Eve of Election: A Fractured Ukraine, United in Uncertainty

10.23 George Soros: Russia poses existential threat to Europe

10.23 Oil slump leaves Russia even weaker than decaying Soviet Union

10.22 World War III: It's Here And Energy Is Largely Behind It

10.22 Sweden bathes in echoes of cold war drama as submarine hunt continues

10.22 Daily Life in the Shadow of ISIS

10.21 Afghan opium poppy yield hits all-time high

We are a non-profit Internet-only newspaper publication founded in 1973. Your donation is essential to our survival.

You can also mail a check to:
Baltimore News Network, Inc.
P.O. Box 42581
Baltimore, MD 21284-2581
Google
This site Web
  Big Pharma Wins Big in Health Care Reform

COMMENTARY:

Big Pharma Wins Big in Health Care Reform

by James Ridgeway
First published in his blog Unsilent Generation yesterday, 22 March 2010
To a large extent, the “debate” over health care was a show debate, an extended round of Washington smoke and mirrors. The administration early on cut its deal with Big Pharma, and pretty much stuck to it throughout the process.

The Republicans look a sour lot this morning, but the pharmaceutical industry, which helps foot the campaign bills of a sizeable chunk of members of both parties, is delighted with the legislation, and with its Democratic friends in the White House and on the Hill.

Members of Congress in both parties generally have lined up behind the insurance and pharmaceutical industries from the get go. So it should come as no surprise that the Democrats, who long ago gave up any pretence of opposing corporate power, found a way to accomodate the pharmaceutical companies on the way to its tepid reform. To a large extent, the “debate” over health care was a show debate, an extended round of Washington smoke and mirrors. The administration early on cut its deal with Big Pharma, and pretty much stuck to it throughout the process.

In fact, the Dems actually made the drugsters look good, celebrating the industry’s generous “concessions” and “discounts” while ensuring that no real threat to Big Pharma’s profits would make their way into the final bill.

The industry’s main goal from the very beginning has been to fend off any government power to negotiate or seriously regulate drug prices–and this they did.

Big Pharma’s second big win was to prevent any measure that would have opened the way for American consumers to buy less expensive drugs abroad, especially from Canada.

At the same time, the supposed give-backs by the drug industry are projected to more than pay for themselves. The much-lauded discounts on brand name drugs for seniors in the Medicare prescription drug program, for example, are good for Big Pharma because they discourage oldsters from switching to generics.

And more insured people simply mean more money coming into the coffers, for Big Pharma as well as for the insurance industry.

Confirmation of the industry analysis came early in the day from the stock market, where drug stocks initially remained level; there certainly was no rush to dump shares, which is what would be expected if the bill actually represented any threat to profits. And by 1 p, EST, CNN Money was reporting a rally in health care stocks.

“I was unable to find anything in there that would cause me to have anxiety if I were a shareholder in a pharmaceutical company,” Ira Loss, a senior health-care analyst at the research firm Washington Analysis, told Dow Jones. According to the ticker story:

Billy Tauzin, who led the industry’s negotiations on health care with lawmakers, said overall drug makers fare well. “While we’re not totally happy,” Tauzin began, “we generally feel like it tracks with our principles.”

Sanofi-Aventis SA (SNY) Chief Executive Christopher Viehbacher said in an interview that the impact of the legislation will be neutral to slightly negative “but better for the industry than if healthcare reform didn’t pass.”

Tauzin, head of the Pharmaceutical Research and Manufacturers of America or PhRMA, and Viehbacher said getting protection for brand-name biologics is among the important provisions for the industry. Drug makers pushed hard to get 12 years of exclusive market protection while the White House and some lawmakers wanted to lower the protection to seven years.

Despite fees and rebates imposed by the legislation, “analysts say drug makers will end up recouping those costs through new customers: The bill would provide insurance coverage to an additional 32 million Americans.” The Dow Jones story continues:

Chalk up another good round for Pharma and Biotech in health care reform,” began a note to clients Friday from Concept Capital, a research firm.Ken Tsuboi, co-manager of the Allianz RCM Wellness Fund, sees the impact of bill, and its $90 billion in concessions over 10 years, as relatively minor in an industry that has annual global sales of about $750 billion, with about $300 billion in the U.S., and margins close to 30%.”I think that it is actually a pretty good deal for Pharma,” Tsuboi said.

The GOP, which purports to be the party of big business, ought to be applauding at least these portions of the health care reform—and perhaps when the cameras go away, some of them will quit bitching and count their blessings. As for the obnoxious Tea Party gang, if they start threatening the real power in this country, which is vested in corporations, they may well find themselves whipped and isolated.


Born in 1936, James Ridgeway has been reporting on politics for more than 45 years. He is currently Senior Washington Correspondent for Mother Jones, and recently wrote a blog on the 2008 presidential election for the Guardian online. He previously served as Washington Correspondent for the Village Voice; wrote for Ramparts and The New Republic; and founded and edited two independent newsletters, Hard Times and The Elements.

Ridgeway is the author of 16 books, including The Five Unanswered Questions About 9/11, It’s All for Sale: The Control of Global Resources, and Blood in the Face: The Ku Klux Klan, Aryan Nations, Nazi Skinheads, and the Rise of a New White Culture. He co-directed a companion film to Blood in the Face and a second documentary film, Feed, and has co-produced web videos for GuardianFilms.

Additional information and samples of James Ridgeway’s work can be found at JamesRidgeway.net and at his newest web site, Solitary Watch.

This article is republished in the Baltimore Chronicle with permission of the author.



Copyright © 2010 The Baltimore News Network. All rights reserved.

Republication or redistribution of Baltimore Chronicle content is expressly prohibited without their prior written consent.

Baltimore News Network, Inc., sponsor of this web site, is a nonprofit organization and does not make political endorsements. The opinions expressed in stories posted on this web site are the authors' own.

This story was published on March 23, 2010.
 



Public Service Ads:
Verifiable Voting in Maryland